Drug Profile
Research programme: nicotinic receptor agonists - University of Minnesota
Alternative Names: Chromaperidine; ChromaprolineLatest Information Update: 21 May 2007
Price :
$50
*
At a glance
- Originator University of Minnesota
- Class
- Mechanism of Action Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 21 May 2007 No development reported - Preclinical for Alzheimer's disease in USA (unspecified route)
- 22 Jan 2003 Preclinical trials in Alzheimer's disease in USA (unspecified route)